Eli Lilly raises revenue outlook as drug sales soar
By The BriefBrief
Eli Lilly raised its revenue outlook, with demand for its weight-loss drugs driving a surge in profits. Zepbound sales soared, and the drug continued to dominate the U.S. prescription weight-loss market. The reporting differs on whether Lilly raised its outlook for the second or third time this year.
WHO:Eli Lilly
WHAT:Eli Lilly raised its revenue outlook as demand for its weight-loss drugs increased.
WHEN:Reported Oct 29, 2026 at 7:51 AM ET
WHERE:USA
WHY:Demand for Eli Lilly’s weight-loss drugs, including strong Zepbound sales, drove the profit surge and outlook increase.
Reporting from 2 identified publishers across this event arc.
